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Abstract
Background: Chemotherapy for pancreatic carcinoma often has severe side effects that limit its efficacy.
The glucocorticoid (GC) dexamethasone (DEX) is frequently used as co-treatment to prevent side effects
of chemotherapy such as nausea, for palliative purposes and to treat allergic reactions. While the potent
pro-apoptotic properties and the supportive effects of GCs to tumour therapy in lymphoid cells are well
studied, the impact of GCs to cytotoxic treatment of pancreatic carcinoma is unknown.
Methods: A prospective study of DEX-mediated resistance was performed using a pancreatic carcinoma
xenografted to nude mice, 20 surgical resections and 10 established pancreatic carcinoma cell lines. Anti-
apoptotic signaling in response to DEX was examined by Western blot analysis.
Results: In vitro, DEX inhibited drug-induced apoptosis and promoted the growth in all of 10 examined
malignant cells. Ex vivo, DEX used in physiological concentrations significantly prevented the cytotoxic
effect of gemcitabine and cisplatin in 18 of 20 freshly isolated cell lines from resected pancreatic tumours.
No correlation with age, gender, histology, TNM and induction of therapy resistance by DEX co-treatment
could be detected. In vivo, DEX totally prevented cytotoxicity of chemotherapy to pancreatic carcinoma
cells xenografted to nude mice. Mechanistically, DEX upregulated pro-survival factors and anti-apoptotic
genes in established pancreatic carcinoma cells.
Conclusion: These data show that DEX induces therapy resistance in pancreatic carcinoma cells and raise
the question whether GC-mediated protection of tumour cells from cancer therapy may be dangerous for
patients.
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Background
Pancreatic cancer remains an unfortunate disease with a 5-
year survival rate below 1%. Thus, it represents one of the
leading causes of cancer related death in industrialized
countries despite advances in medical therapy and surgi-
cal techniques [1]. One of the major hallmarks of pancre-
atic cancer is its early systemic dissemination and its
extraordinary local tumour progression. These features
may contribute to more than 3/4 of patients diagnosed
with this disease who cannot be offered curative treatment
and, therefore, may determine the high mortality rate
among patients with pancreatic cancer [2]. Surgery is the
mainstay of treatment. Chemotherapy is important in
controlling residual disease following surgery and may be
used as neoadjuvant therapy in patients with advanced
disease. The standard chemotherapy for advanced pancre-
atic cancer is currently gemcitabine. Alternatively, combi-
nations of mitomycin C, cisplatin and 5-fluorouracil [3]
may be used and are routinely given together with dexam-
ethasone (DEX), a synthetic glucocorticoid (GC).
DEX and similar GCs were first introduced to tumour
therapy on the basis of pro-apoptotic effects in lymphoid
cells and on their effectiveness in treating tumour related
edema, inflammation, pain, and electrolyte imbalance as
well as stimulating appetite, and most importantly, pre-
venting nausea and emesis caused by cytotoxic drugs [4-
8]. However, controlled randomized trials evaluating a
potential impact of GCs on growth of solid tumours and
patient survival have never been performed. Concerns
about the widespread use of GCs during therapy of solid
tumours have been expressed repeatedly [9,10] involving
studies showing enhanced percentages of metastases in
breast cancer patients [11,12] or an increased risk of skin
cancer and non-Hodgkin lymphomas among users of sys-
temic GCs [13]. Recent studies suggest inhibition of cyto-
toxic therapy-induced apoptosis by DEX in established
lung, cervical and breast carcinoma cell lines [14-16]. For
inhibition of apoptosis a functional glucocorticoid recep-
tor (GR) is required and association with the transcrip-
tional induction of survival molecules like serum and GC-
inducible protein kinase-1 (SGK-1) and mitogen-acti-
vated protein kinase phosphatase-1 (MKP-1) is suggested
in human established breast cancer cell lines [15]. Thus,
treatment with a GC alone or combined with chemother-
apy led to an increased protein expression of SGK-1 and
MKP-1 while specific inhibition of these molecules by
small interfering RNA reversed the anti-apoptotic effects
of GC treatment in breast cancer cells [15].
To analyze whether DEX might affect the outcome of cyto-
toxic therapy of pancreatic carcinomas, cell lines and
tumour cells freshly isolated from resected pancreatic can-
cer specimen as well as a tumour xenograft on nude mice
were examined. Cells were treated in vitro or ex vivo with
gemcitabine or cisplatin in the presence or absence of
DEX. DEX inhibited apoptosis and promoted prolifera-
tion of the cancer cells independently of age, gender, his-
Table 1: Calculation of resistance for tumour probe 2.
Time Drug Treatments DEX1 DEX2 DEX3 Sum
24 h 0 8/8/8/8 0 0 0 0
1 8/8/5/5 0 1 1 2
2 7/8/4/8 0 1 1 2
3 7/8/8/7 0 1 1 2
48 h 0 8/8/8/8 0 0 0 0
1 8/8/8/8 0 1 1 2
2 8/8/8/8 0 1 1 2
3 8/8/8/8 0 1 1 2
72 h 0 7/8/6/7 0 1 0 1
1 3/7/6/4 0 0 1 1
2 7/8/6/8 0 1 1 2
3 8/5/8/8 0 1 1 2
Time: Cells were treated with chemotherapy for 24, 48 or 72 h. Drug: Cells were left either untreated (0) or were treated with three different 
concentrations of chemotherapy (1, 2, 3). Treatments: the number of repeated measurements from which means and standard deviations were 
calculated are indicated. DEX1, DEX2, DEX3: Non-drug treated cells (Drug 0) or drug-treated cells (Drug 1, 2, 3) were treated with three different 
concentrations of DEX. The value of 0 or 1 was assigned depending on whether or not the DEX group was declared resistant. There is a maximum 
score of 9 per time point for drug-treated cells. The basal effect of DEX (drug 0 row) was evaluated for its own and is not included in the sum 
column.BMC Cancer 2006, 6:61 http://www.biomedcentral.com/1471-2407/6/61
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DEX inhibits apoptosis and promotes proliferation in response to gemcitabine in vitro Figure 1
DEX inhibits apoptosis and promotes proliferation in response to gemcitabine in vitro. The established pancreatic 
cancer cells MIA-Pa-Ca2, T3M4, DAN-G, Capan-1, Capan-2, PANC-1, Colo-357, AsPC1, SU8686 and BxPc-3 were left either 
untreated (CO) or were treated with gemcitabine (GEM: 25, 50, 200 µM) in the absence (white bars) or presence (black bars) 
of DEX (1 µM) which was added 48 h prior to cytotoxic treatment. 72 h following addition of gemcitabine, (A) apoptosis was 
analyzed by staining of the cells with annexin-FITC and FACS-analysis. (B) Likewise, viability was detected by the MTT-assay. 
Experiments were performed three times with identical outcome and standard deviations are shown.
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tology or TNM and induced therapy resistance even in an
in vivo xenograft model. Differential regulation of expres-
sion of pro-survival factors and anti-apoptotic genes may
be the underlying mechanism for cell-type specific DEX-
induced resistance.
Methods
Pancreatic carcinoma cell lines and culture
The established pancreatic carcinoma cell lines were
derived from the tumour bank of the German Cancer
Research Center (Capan-1, Capan-2, DAN-G), or from the
lab of H. Friess (SU8686, PANC-1, MIA-PaCa2, BxPc-3,
Colo-357, T3M4 and AsPC-1). Cells were grown at 37°C
in DMEM. DMEM was obtained from Life Technologies
DEX inhibits apoptosis and promotes proliferation in response to cisplatin in vitro Figure 2
DEX inhibits apoptosis and promotes proliferation in response to cisplatin in vitro. Cells were treated and analyzed 
as described in Fig. 1 except that cisplatin (7, 13 µM) was used instead of gemcitabine.
A
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Gibco BRL (Karlsruhe, Germany) supplemented with
10% heat-inactivated fetal bovine serum (Sigma, Deisen-
hofen, Germany), 25 mM HEPES and 2 mM L-glutamine
(all from Gibco/Life Technologies, Paisley, Scotland).
Isolation of fresh tumour cells from resected pancreatic 
cancer specimen
Solid tumours fromfreshpancreatic carcinomas were
minced in RPMI medium supplemented with 20% heat-
inactivated fetal bovine serum (Sigma, Deisenhofen, Ger-
many), 25 mM HEPES, 2 mM L-glutamine and Pen/Strep
(all from Gibco/Life Technologies, Paisley, Scotland)
under sterile conditions, counted by trypan blue exclusion
and immediately analyzed by the MTT-assay. Patient
material was obtained under the approval of the ethic
committee of the University of Heidelberg. Diagnoses
were established by conventional clinical and histological
criteria according to the World Health Organization
(WHO). All surgical resections were indicated by princi-
ples and practice of oncological therapy.
Nude mice and xenografts
Cells of the pancreatic carcinoma cell line MIA-PaCa2
were injected subcutaneously into the right anterior flank
of 6-10 weeks old NMRI (nu/nu) female mice. After the
tumours had reached a mean diameter of about 8-10 mm,
mice carrying MIA-PaCa2 xenografts were randomized
divided into groups of 5-6 animals each and treatment
was started. The mice were given 0.28 mg/l DEX in the
drinking water, and the daily amount of water consumed
was approximately 30 ng/g body weight. A mouse with a
body weight of 25 g drinks 2.5 ml (1/10 body weight) per
day corresponding to a serum concentration of about 0.07
µM DEX. Two days after adding DEX to the drinking
water, therapy with cisplatin was started (day 0). Cisplatin
(5 mg/kg) was injected at two consecutive days (day 2 and
day 3). In detail, we diluted 10 mg cisplatin in 20 ml PBS
(0.5 mg CIS/ml) and injected 0.01 ml of this solution per
g mouse. That means, we injected 0.25 ml in a mouse of
25 g body weight. Tumour growth was followed by meas-
uring two diameters daily with calipers and tumour vol-
umes (v) were calculated using the formula v = 1/2
(length × width2). Mice were humanely euthanized at
tumour sizes > 3000 mm3. Animal experiments have been
carried out in the animal facilities of the DKFZ after
approval by the authorities (Regierungspräsidium Karl-
sruhe).
Drugs
A stock solution of cisplatin (Sigma, Deisenhofen, Ger-
many) was prepared in DMSO at the concentration of 33
mM. Gemcitabine (kind gift from Eli Lilly, Indianapolis,
IN, USA) was diluted in PBS to a 50 µM stock. A 25 mM
stock of DEX (Sigma) was prepared in ethanol. Final con-
centrations of the solvents in medium were 0.1% or less.
Measurement of apoptosis
Cells were stained with fluoresceinthiocyanate (FITC)-
conjugated annexin V (BD Biosciences, Heidelberg, Ger-
many) and externalization of phosphatidylserine as well
as the forward side scatter profile were identified by flow
cytometry (FACScan, BD Biosciences) as described [14].
In parallel, DNA-fragmentation was measured by the
nicoletti method as described [17] or cell morphology was
determined by the FSC/SSC profile.
MTT-assay
Primary tumour cells were resuspended at 5 × 105/ml in
96-well microplates, 100 µl per well. After treatment, the
MTT-assay was performed as recently described [16].
DEX-pretreated cells are protected despite three weeks  incubation with gemcitabine in vitro Figure 3
DEX-pretreated cells are protected despite three 
weeks incubation with gemcitabine in vitro. AsPC1 
cells were left untreated (CO) or were treated with 0.1 µM 
DEX (DEX), 25 µM GEM (GEM), or both together (DEX/
GEM). One, two and three weeks later the amount of viable 
cells was determined by trypan blue exclusion and cells were 
photographed after two weeks of incubation. Experiments 
were performed three times with identical outcome.
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DEX inhibits the therapeutic effect of gemcitabine ex vivo Figure 4
DEX inhibits the therapeutic effect of gemcitabine ex vivo. (A) Tumour cells from a patient (No. 1) with pancreatic 
cancer were freshly isolated and cultivated in a concentration of 5 × 105/ml in the absence (white bars) or presence of DEX 
(0.1, 1 or 10 µM as indicated) for 24 h. Gemcitabine was added (25, 50, 200 nM GEM) while the controls remained either 
untreated (CO) or were treated with the solvents alone (EtOH, used for dilution of DEX and DMSO, used for dilution of gem-
citabine and cisplatin). 48 h after adding gemcitabine or solvents alone, viability was measured by the MTT-assay. (B) Tumour 
cells from patients with pancreatic cancer (No. 2-10) were freshly isolated, cultivated, and analyzed as described above. Eight 
wells per treatment were analyzed and standard deviations are less than 10%. Statistical analysis of significance of DEX-induced 
resistance is shown in Table III.
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Western blot analysis
Equal numbers of cells in each experimental condition
were lysed with 2 x Laemmli buffer and were fractionated
on 10% SDS-PAGE gels. The fractionated proteins were
transferred to nitrocellulose and were stained with Pon-
ceau S dye to confirm equal protein loading. The mem-
branes were then rinsed and incubated in the rabbit
polyclonal antibodies MKP-1, BAG-1 (both from Santa
Cruz, Heidelberg, Germany), SGK-1 (Stressgene, Victoria,
Canada), X-IAP (New England Biolabs/Cell Signaling,
Frankfurt, Germany) or in the mouse monoclonal anti-
bodies: BCL-2 (Merck/Calbiochem, Darmstadt, Ger-
many), ACTIN (clone C4, ICN, Aurora, Ohio, USA).
Bound antibodies were detected by anti-rabbit or anti-
mouse/horseradish peroxidase conjugates (Santa Cruz)
and enhanced chemiluminescence system.
Statistical analysis
Surgical specimen
each tumour probe was investigated in a 2-factorial design
consisting of three doses of DEX (0.1 = DEX1, 1 = DEX2,
10 µM = DEX3) and a control and three doses of gemcit-
abine (25 nM = 1; 50 nM = 2; 200 nM = 3) or cisplatin (7
µM = 1; 17 µM = 2; 34 µM = 3) and a control (= 0). This
results in a total of 16 experimental conditions. Viability
of the cells under each condition was determined as mean
of 3 to 8 replicates together with its standard deviation
and then standardized on the result of the double control
(no cytotoxic agent and no DEX applied); i.e. the viabili-
ties of all conditions were divided by the mean of the dou-
ble control. For each tumour probe the standardized
means were compared separately for each therapeutic
dose and for the control by comparing the three DEX
doses with its respective control (cisplatin or gemcitabine
treatment alone). Notice, that the four means (three DEX
doses and control) under the condition of no therapy
describe the effect of DEX alone while the other three sets
of four means under the three doses of the therapeutic
agent describe the resistance of the cells under treatment
depending on DEX. We declared a DEX dose group resist-
ant when its mean minus one standard deviation (  -
SDj) was still larger than the mean plus one standard devi-
ation (  + SD0) of the respective control group of that
tumour probe, j = 1, 2, 3 denoting the three dose groups
receiving cytotoxic drugs. On this basis, scores were calcu-
lated per therapeutic dose (values 0, 1, 2, 3) as well as per
tumour probe in total (values ranging from 0 to 9). A
tumour probe was declared as being significantly resistant
to cytotoxic treatment when it showed a score of 2 for at
least one drug dose or when it reached the total score of 5
Xj
X0
DEX inhibits the therapeutic effect of cisplatin ex vivo Figure 5
DEX inhibits the therapeutic effect of cisplatin ex vivo. (A) Tumour cells from patients (No. 11-20) with pancreatic can-
cer were isolated, cultivated and analyzed as described in Fig. 4, except of that cisplatin (7, 17 34 µM) was used instead of gem-
citabine.
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out of a maximum of 9 per time point (i.e. more than
50%). A calculation is given as example in Table 1 for
tumour probe 2.
Please note, that the scores and definition of resistance
have been exclusively designed for the present study by L.
Edler and W. Rittgen from the Department of Biostatistics,
German Cancer Research Center.
The outcomes of a group of tumour probes were summa-
rized in respective ratios obtained by adding the individ-
ual scores for each condition as well as in total over the
number of probes and by dividing through the number of
probes (compare Table 1). The results of the evaluation of
each single tumour probe are available upon request. The
tumour population was considered as suffering from
resistance as a whole, when for one therapeutic dose all
ratios were higher than 50% or when 5 of the total of 9
combinations were higher than 50%. The statistical
method described was applied independently to all three
time points.
Established cell lines
Corresponding to the analysis of patient-derived tumour
probes, cell lines were investigated in a 2-factorial design
consisting of one dose of DEX (1 µM) and a control and
three doses of cytotoxic treatment and a control resulting
in a total of 8 experimental conditions. Viability of the
cells under each condition was determined as mean of 8
replicates (MTT-assay) or as mean of 6 replicates (apopto-
sis) as described above.
Xenografts on nude mice
A distribution free test for tumour growth curve analyses
was used for therapy experiments with xenografted cancer
cells as described [18].
Results
DEX induces resistance towards gemcitabine and cisplatin 
in vitro
To investigate whether DEX might protect pancreatic car-
cinoma cell lines by interfering with apoptosis we treated
MIA-Pa-Ca2, T3M4, DAN-G, Capan-1, Capan-2, PANC-1,
Colo-357, AsPC1, SU8686 and BxPc-3 cells with gemcit-
abine or cisplatin in the presence or absence of DEX. 72 h
later, apoptosis was detected by annexin-FITC followed by
FACS-analysis. While cytotoxic drugs alone strongly
induced apoptosis, the presence of DEX inhibited this
effect in all cell lines examined (Fig. 1A, 2A). No induc-
Table 3: Statistical significance of DEX-induced resistance in 
patients.
Patient No. 24 h 48 h 72 h
1S S S
2S S S
3S S S
4S S S
5S S S
6S S S
7N S S N S
8S S N S
9 S NS NS
10 NS NS S
11 S S S
12 S S S
13 S NS S
14 S S S
15 ND S ND
16 ND S ND
17 S S S
18 S NS NS
19 NS NS NS
20 NS NS NS
Significance of DEX-induced resistance (compare Fig. 4, 5 and Fig. II-
V) in patient-derived cells was analysed as described in the Material 
and Methods section.
S = significant
NS = non-significant
ND = not done
Table 2: DEX-induced resistance in fresh patient-derived 
pancreatic tissue.
Time No. of 
patients
Drugs DEX1 DEX2 DEX3 Sum
24 h 18 0 11% 22% 11% 15%
1 44% 78% 83% 69%
2 44% 67% 56% 56%
3 56% 72% 90% 72%
48 h 20 0 10% 15% 15% 13%
1 60% 70% 90% 73%
2 50% 75% 65% 63%
3 60% 75% 70% 68%
72 h 18 0 56% 28% 17% 17%
1 44% 72% 67% 61%
2 39% 67% 67% 57v
3 56% 67% 78% 67%
Sum of 
drug-
treated 
cells 1-3
50% 71% 74%
Sum of 
control 
cells 0
9% 22% 14%
The percentage of cells derived from 20 patients which show 
statistically significant chemotherapy resistance/enhanced viability in 
response to treatment with dexamethasone is given. For definition of 
resistance, please see the Material and Methods section. Time: time 
point after incubation with drugs; No. of patients: indicates the 
number of patients whose cells were freshly isolated from resected 
pancreatic tissue (compare Table 2); 0: without drugs, 1: low drug 
concentration, 2: medium drug concentration, 3: high drug 
concentration of gemcitabine (25, 50 200 nM) or cisplatin (7,17,34 
µM). DEX1: 0.1 µM, DEX2: 1 µM, DEX3: 10 µM.BMC Cancer 2006, 6:61 http://www.biomedcentral.com/1471-2407/6/61
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tion of apoptosis occurred in untreated cells or cells
treated with the solvents alone. These data are confirmed
by the measurement of DNA-fragmentation by the
nicoletti method or by determining the cell morphology
by the FSC/SSC profile and FACS-analysis " [see 1]". In
light of inhibited apoptosis we next analyzed whether
DEX might influence growth of pancreatic carcinoma cell
lines treated with cytotoxic drugs. The same set of cells was
treated as described above and viability was detected by
the MTT-assay. While gemcitabine or cisplatin alone
strongly reduced viability, the presence of DEX dimin-
ished the cytotoxic effect in all cell lines (Fig. 1B, 2B). In
order to know whether this protective effect of DEX might
be long lasting we treated pancreatic cancer cells with DEX
in the presence or absence of gemcitabine. One, two and
three weeks later viable cells were counted by trypan blue
exclusion and cells were photographed after two weeks
(Fig. 3). DEX strongly enhanced basal proliferation and
increased the viability of gemcitabine-treated cells above
levels of untreated controls. Thus, DEX inhibits apoptosis
and promotes proliferation of pancreatic carcinoma cells
after treatment with cytotoxic drugs in vitro.
DEX induces resistance towards gemcitabine and cisplatin 
ex vivo
To examine the ex vivo effect of DEX we isolated tumour
cells from pancreatic cancer specimen immediately after
resection. The pancreatic tissue used contained 90% pan-
creatic tumour cells morphologically identified by a
pathologist. DEX was used in concentrations of 0.1, 1 and
10 µM from which the median concentration resembles
peak plasma levels in the clinical setting [6,19,20]. Cells
derived from 20 patients were treated with three concen-
trations each of gemcitabine or cisplatin in the presence or
absence of low, median and high concentrations of DEX.
24, 48 and 72 h later viability was measured (Fig. 4, 5)
and [see Additional Files 2, 34, 5]". While cytotoxic drugs
alone strongly reduced viability in all cells, viability was
significantly enhanced in 18 of 20 examined primary cell
lines. Using statistical analysis viability was significantly
enhanced in 50% of cells treated with 0.1 µM DEX, in
71% of cells treated with 1 µM DEX and in 74% of cells
treated with 10 µM DEX as calculated from the means of
data obtained with three concentrations of cytotoxic ther-
apy at 24, 48 and 72 h after treatment (Table 2, 3). Even
DEX alone significantly enhanced basal viability at the
low concentration in 9%, at the median concentration in
22% and at the high concentration in 14% of cells while
solvents alone had no effect (Fig. 4A and Table 2). Induc-
DEX inhibits therapy-induced carcinoma regression in vivo Figure 6
DEX inhibits therapy-induced carcinoma regression 
in vivo. MIA-Pa-Ca2 tumour cells were established as 
xenograft cell line and injected subcutaneously into nude 
mice treated as described in material and methods. The vol-
umes of the fast-growing tumours are shown from day one 
to five after start of cisplatin therapy. Data are presented as 
mean of 5-6 animals and the single measurements are indi-
cated. Statistical analysis: The P-value of 0.0063 for the CO 
versus CIS versus DEX versus CIS/DEX was determined 
according to the Koziol test for tumour growth curve analy-
ses [18].
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Table 4: Characterization of patient-derived fresh pancreatic 
tissue.
No. Gender Age (years) Histological Typing (WHO) pTNM
1 M 84 adeno pT3, pN1
2 F 55 adenoma
3 F 80 adeno pT3, pN1
4 F 56 adeno pT3, pN0
5 M 44 adeno pT3, pN1
6 F 65 adeno pT3, pN1
7 M 75 adono pT3, pN1
8 M 72 adeno PT3, pN1
9 F 58 adeno pT3, pN1
10 M 74 adeno pT3, pN1
11 F 55 adeno pT3, pN1
12 F 38 adeno pT3, pN1
13 M 71 serous adenoma
14 F 37 acinus cell carcinoma pT3, pN1
15 M 67 adeno pT3, pN1
16 F 58 adeno pT3, pN1
17 F 73 adeno pT3, pN1
18 M 66 adeno pT3, pN0
19 M 67 neuroendocrine
20 M 70 adeno pT3, pN1
M = male, F = female, No. = number of patientBMC Cancer 2006, 6:61 http://www.biomedcentral.com/1471-2407/6/61
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tion of therapy resistance by DEX did neither correlate
with the histological phenotype nor with the tumour
stage, age or gender of patients (Table 4).
DEX induces therapy resistance in vivo
To analyze the in vivo effect of DEX we xenografted MIA-
PaCa2 cells to nude mice. Tumour volumes are shown at
day one to five after start of cisplatin therapy and found to
be reduced in mice treated with cisplatin alone (Fig. 6).
However, DEX totally prevented the growth-inhibiting
effect of cisplatin since the tumours grew as fast as those
of untreated control mice.
Upregulation of survival- and anti-apoptotic molecules by DEX Figure 7
Upregulation of survival- and anti-apoptotic molecules by DEX.(A) Capan-1 cells were treated with DEX (1 µM) for 
24, 48 or 72 h as indicated. Cells were lysed, proteins were harvested and analyzed by Western blot analysis. (B) MIA-Pa-Ca2, 
SU8686, T3M4, Capan-2, AsPC1 and PANC-1 were treated as described in Fig. 1. 48 h later proteins were harvested. Western 
blot analysis using antibodies toward BAG-1 and HSP-70 were performed. The p50, p36 and p29 subunits of BAG-1 as well as 
the band of HSP-70 are indicated. ACTIN expression is a marker for equal conditions. Antibodies used are: MKP-1 (42 kD), 
SGK-1 (50-55 kD), X-IAP (57 kD), Bcl-2 (28 kD), BAG-1 (p50, p36 and p29 subunits) HSP-70 (70 kD) and ACTIN (44 kD). The 
experiments have been performed three times with similar outcome.
MKP-1
SGK-1
ACTIN
HSP70
Bcl-2
X-IAP
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MKP-1, SGK-1, X-IAP and Bcl-2 but not BAG-1 may be 
involved in DEX-induced resistance
In a recent study we demonstrated that DEX-co-treatment
induces apoptosis resistance in an established lung and
cervical carcinoma cell line but not in leukemic T cells.
This was due to differential regulation of diverse apoptosis
genes and depends on a functional GR [14]. The upstream
mechanism by which DEX inhibits apoptosis and pro-
motes proliferation in pancreatic carcinomas is totally
unknown. Therefore, we analyzed the expression of BAG-
1, known to link GR-signaling to impaired apoptosis and
enhanced proliferation by interaction with HSP-70 [21]
by Western blot analysis. While the p50 subunit of BAG-1
could be detected in all cell lines examined, the p36 sub-
unit was only present in MIA-Pa-Ca2, Capan-1 and
Capan-2 cells, while the p29 subunit was only present in
MIA-Pa-Ca2, SU8686, Capan-1, Capan-2, ASPC-1 and
weakly in PANC-1 cells (Fig. 7A, 7B). Induction of either
subunit by DEX alone or in combination with cisplatin
did not occur. Also, HSP-70, the co-worker of BAG-1, is
equally and strongly expressed under any condition in all
cell lines except MIA-Pa-Ca2 expressing only minimal
amounts of HSP-70. As a control, we examined expression
of GR, and found the protein product whose level was
also not changed in response to cisplatin and/or DEX
(data not shown). Since enhanced expression of MKP-1
and SGK-1 has been recently described to be involved in
DEX-induced resistance in established breast cancer cell
lines [15], we examined expression of these pro-survival
molecules in pancreatic cancer cells by Western blot anal-
ysis together with expression of the anti-apoptotic mole-
cules X-IAP and Bcl-2. During a time kinetic from 24 to 72
h, DEX strongly enhanced the levels of MKP-1, SGK1 and
X-IAP, in several pancreatic cancer cell lines examined,
while Bcl-2 expression was only marginally increased.
Representative data with Capan-1 cells are shown (Fig.
7A). Therefore, enhanced expression of MKP-1, SGK-1, X-
IAP and Bcl-2 but not of BAG-1 may be involved in DEX-
induced therapy resistance of pancreatic carcinomas.
Discussion
Our data demonstrate for the first time that in vitro, ex vivo
and in vivo treatment of pancreatic cancer cells with GCs
induces resistance towards cytotoxic therapy. We report
here, that DEX inhibits gemcitabine- and cisplatin-
induced apoptosis and promotes proliferation in all of ten
examined established pancreatic cancer cell lines, in 18 of
20 primary pancreatic tumour cell lines isolated from can-
cer specimen and in xenografted pancreatic tumour cells.
These results suggest a cell type specific effect of GCs, since
these agents are well known to act pro-apoptotic and anti-
proliferative in lymphoid cells [10,22]. The observed
induction of therapy resistance by DEX in pancreatic car-
cinoma did neither correlate with the histological pheno-
type nor with the tumour stage, age or gender of patients
corresponding to our recent results obtained with DEX-
treated malignant cells from lung [16], prostate, kidney,
bladder, testis [23], colon, rectum, liver [24] and ovary
[25]. Thus, our results obtained with pancreatic carcino-
mas may be transferred to other solid tumours, since we
found induction of resistance by GCs in 95% of more
than 160 examined fresh surgical specimen, xenografts on
mice and established cell lines of tumours including blad-
der, bone, brain, breast, cervix, colon, liver, lung, kidney,
ovary, prostate, rectum and testis, together with neurob-
lastomas, and melanomas (compare our recent manu-
scripts [16,23-25]and our unpublished work). Thus, the
present findings strongly suggest that GCs are highly sus-
picious to induce resistance to cytotoxic therapy in clinical
settings, specifically, in patients with pancreatic cancer.
This point was recently addressed in a retrospective clini-
cal study evaluating records of 245 of a total of 763
patients with ovarian carcinoma and no negative outcome
of GC treatment on survival of patients was found [26].
However, this study cannot give a definitive answer to the
question of whether GC treatment, given as part of anti-
emetic regimen, prevention of allergic reactions or as
immunosuppressive therapy is safe in patients with ovar-
ian carcinoma or other solid tumours – the reasons are
discussed elsewhere [27]. Furthermore, there are other
clinical examinations which clearly show a negative
impact of GCs, e.g. an increased metastatic potential in
breast cancer patients and an enhanced risk of skin cancer
and lymphomas among users of systemic GCs [11-13].
The mechanisms by which GCs induce apoptosis in lym-
phoid cells are well studied. These include depolarization
of the mitochondrial membrane potential, enhanced
expression of the death receptor CD95 and its ligand, fol-
lowed by activation of the caspase cascade [28-30]. The
same mechanisms that are induced in lymphoid cells are
blocked in several carcinoma cells by GCs thereby inhib-
iting chemo- and radiation therapy-induced apoptosis
[14,15].An open question is, how GCs mediate these cell-
type specific effects clearly shown to be related to a func-
tional glucocorticoid receptor (GR) [14,15]. Nothing is
known about a direct link between GR signaling and
induction of apoptosis. One candidate molecule is the
anti-apoptotic co-chaperone BAG-1 which together with
the chaperone HSP-70 is involved in regulation of GR
binding activity [21]. However, DEX did not up-regulate
expression of BAG-1 in our studies, neither basal, nor in
the presence of cisplatin, as would have been expected in
the case of an anti-apoptotic influence of BAG-1 on GR
signaling. In contrast, we found DEX-induced upregula-
tion of the pro-survival genes SGK-1 and MKP-1. This is in
line with another report demonstrating that downregula-
tion of MKP-1 in both pancreatic cancer and chronic pan-
creatitis suppresses tumourigenicity of pancreatic cancer
cells [31]. Similarly, Bcl-2 overexpression has been associ-BMC Cancer 2006, 6:61 http://www.biomedcentral.com/1471-2407/6/61
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ated with acquired resistance of pancreatic carcinoma [32]
corresponding to our data which show upregulation X-
IAP and to a somehow weaker extent of Bcl-2 in response
to DEX. Therefore, cell type-specific anti-apoptotic and
pro-proliferative signaling may be involved in induction
of resistance by GCs in pancreatic carcinoma cells.
Another possible explanation for the cell-type specific
anti-apoptotic properties of GCs may be the differential
expression of GR co-activators and co-repressors in diverse
cell types, as proposed to explain the opposite effects of
tamoxifen on mammary versus endometrial tissue [33]. A
recent study compared gene expression of a breast cancer
cell line with genes found to be regulated by DEX in lym-
phocytes [15]. Surprisingly, only a few of the genes regu-
lated by DEX in carcinomas are the same as those
identified as GC-regulated in lymphocytes. Among the
differential regulated set of sequences are apoptotic genes
as well as genes involved in signal transduction, metabo-
lism, transcription, cell cycle, DNA repair and others.
These recent data strongly suggest that tissue-specific dif-
ferences in GC-induced apoptosis versus survival out-
comes may be due to cell-type-specific transcriptional
regulation.
Conclusion
In conclusion, we show by in vitro,ex vivo and in vivo stud-
ies that application of DEX renders pancreatic cancer cells
resistant to apoptosis and promotes proliferation follow-
ing cytotoxic therapy. This is in contrast to the effect of
GCs in lymphoid cells and may involve cell type specific
regulation of survival molecules such as SGK-1 and MKP-
1 together with anti-apoptotic molecules such as X-IAP
and Bcl-2. Thus, while some properties of GCs may be of
benefit, induction of resistance in tumour cells towards
cancer therapy may be dangerous for patients. Prospective
clinical studies which do not exist until now, are urgently
needed.
Abbreviations
Dexamethasone (DEX), Glucocorticoids (GCs), Glucocor-
ticoid Receptor (GR)
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
CZ: performed the experiments with primary and estab-
lished cell lines
AK: selected tumors and participated in creating the stud-
ies
PB: has been involved in drafting the manuscript for
important intellectual content
ACBC: has been intellectually involved in studying mech-
anisms of DEX-induced resistance and in preparation of
the manuscript
JM: performed the xenograft studies
WR: performed statistical analyses
LE: performed statistical analyses
KMD: was involved in drafting the manuscript critically
for important intellectual content
MB: organized transfer of freshly resected tumors
HF: organized transfer of freshly resected tumors and par-
ticipated in design of the studies and preparation of the
manuscript
IH: concepted and designed the study, analysed and inter-
pretated the data and wrote the manuscript
All authors read and approved the final manuscript
Additional material
Additional File I
DEX inhibits apoptosis in response to gemcitabine in vitro The estab-
lished pancreatic cancer cells T3M4, Colo-357 and Capan-2 were left 
either untreated (CO) or were treated with gemcitabine (GEM: 25, 50, 
200 µM) in the absence (white bars) or presence (black bars) of DEX (1 
µM) which was added 48 h prior to cytotoxic treatment. 72 h following 
addition of gemcitabine, (A) apoptosis was analyzed by staining of the 
cells with annexin-FITC (% APOPTOSIS), with nicoletti buffer (% 
DNA-FRAGMENTATION) and FACS-analysis or cells were left 
unstained and cell morphology was analyzed by FACS analysis (% CELL 
DEATH).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-6-61-S1.pdf]
Additional File II
DEX induces resistance ex vivo Tumour cells from 20 patients (No. 1-
20) with pancreatic cancer were freshly isolated and cultivated in a con-
centration of 5 × 105/ml in the absence (white bars) or presence of DEX 
(0.1, 1 or 10 µM as indicated) for 24 h. Gemcitabine or cisplatin were 
added in concentrations indicated while the controls remained untreated 
(CO) or were treated with the solvents alone. 24, 48 and 72 h after add-
ing cytotoxic drugs, viability was measured by the MTT-assay. Eight wells 
per treatment were analyzed and standard deviations are less than 10%.
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2407-6-61-S2.pdf]BMC Cancer 2006, 6:61 http://www.biomedcentral.com/1471-2407/6/61
Page 13 of 14
(page number not for citation purposes)
Acknowledgements
We thank M. Mildenberger for excellent technical assistance and the 
Tumorzentrum Heidelberg for financial support.
References
1. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H,
Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L,
Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Buchler MW: Adju-
vant chemoradiotherapy and chemotherapy in resectable
pancreatic cancer: a randomised controlled trial.  Lancet 2001,
358(9293):1576-1585.
2. Keleg S, Buchler P, Ludwig R, Buchler MW, Friess H: Invasion and
metastasis in pancreatic cancer.  Mol Cancer 2003, 2(1):14.
3. Petty RD, Nicolson MC, Skaria S, Sinclair TS, Samuel LM, Koruth M:
A phase II study of mitomycin C, cisplatin and protracted
infusional 5-fluorouracil in advanced pancreatic carcinoma:
efficacy and low toxicity.  Ann Oncol 2003, 14(7):1100-1105.
4. Cheng L, Du C, Murray D, Tong X, Zhang YA, Chen BP, Hawley RG:
A GFP reporter system to assess gene transfer and expres-
sion in human hematopoietic progenitor cells.  Gene Ther 1997,
4(10):1013-1022.
5. Aapro MS: Present role of corticosteroids as antiemetics.  In
Recent results in cancer research Volume 121. Berlin , Springer Verlag;
1991:91-100. 
6. The Italian Group for Antiemetic Research. Dexametha-
sone, granisetron, or both for the prevention of nausea and
vomiting during chemotherapy for cancer.   N Engl J Med 1995,
332(1):1-5.
7. The Italian Group for Antiemetic Research. Dexamethasone
alone or in combination with ondansetron for the prevention
of delayed nausea and vomiting induced by chemotherapy.
N Engl J Med 2000, 342(21):1554-1559.
8. Kirkbride P, Bezjak A, Pater J, Zee B, Palmer MJ, Wong R, Cross P,
Gulavita S, Blood P, Sun A, Dundas G, Ganguly PK, Lim J, Chowdhury
AD, Kumar SE, Dar AR: Dexamethasone for the prophylaxis of
radiation-induced emesis: a National Cancer Institute of
Canada Clinical Trials Group phase III study.  J Clin Oncol 2000,
18:1960-1966.
9. Haid M: Steroid antiemesis may be harmful.  N Engl J Med 1981,
304:1237.
10. Rutz HP: Effects of corticosteroid use on treatment of solid
tumours.  Lancet 2002, 360(9349):1969-1970.
11. Iversen HG, Hjort GH: The influence of corticoid steroids on
the frequency of spleen metastases in patients with breast
cancer.  Acta Pathol Microbiol Scand 1958, 44:205-212.
12. Sherlock P, Hartmann WH: Adrenal  steroids and the pattern of
metastases of breast cancer.  JAMA 1962, 181:313-317.
13. Sorensen HT, Mellemkjaer L, Nielsen GL, Baron JA, Olsen JH, Karagas
MR: Skin cancers and non-hodgkin lymphoma among users of
systemic glucocorticoids: a population-based cohort study.  J
Natl Cancer Inst 2004, 96(9):709-711.
14. Herr I, Ucur E, Herzer K, Okouoyo S, Ridder R, Krammer PH, von
Knebel Doeberitz M, Debatin KM: Glucocorticoid co-treatment
induces apoptosis resistance toward cancer therapy in carci-
nomas.  Cancer Res 2003, 63:3112-3120.
15. Wu W, Chaudhuri S, Brickley DR, Pang D, Karrison T, Conzen SD:
Microarray analysis reveals glucocorticoid-regulated survival
genes that are associated with inhibition of apoptosis in
breast epithelial cells.  Cancer Res 2004, 64(5):1757-1764.
16. Gassler N, Zhang C, Schnabel PA, Dienemann H, Debatin KM, Mat-
tern J, Herr I: Dexamethasone-induced cisplatin and gemcit-
abine resistance in lung carcinoma samples treated ex vivo.
Brit J Cancer 2005, 92:1084-1088.
17. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccard C: A rapid
and simple method for measuring thymocyte apoptosis by
propidium iodide staining and flow cytometry.  J Immunol Meth-
ods 1991, 139:271-279.
18. Koziol JA, Maxwell DA, Fukushima M, Colmerauer ME, Pilch YH: A
distribution-free test for tumor growth curve analyses with
application to an animal tumor immunotherapy experi-
ment.  Biometrics 1981, 37:383-390.
19. Ioannidis JP, Hesketh PJ, Lau J: Contribution of dexamethasone
to control of chemotherapy-induced nausea and vomiting: a
meta-analysis of randomized evidence.  J Clin Oncol 2000,
18(19):3409-3422.
20. Brady ME, Sartiano GP, Rosenblum SL, Zaglama NE, Bauguess CT:
The pharmacokinetics of single high doses of dexametha-
sone in cancer patients.  Eur J Clin Pharmacol 1987, 32(6):593-596.
21. Cato AC, Mink S: BAG-1 family of cochaperones in the modu-
lation of nuclear receptor action.  J Steroid Biochem Mol Biol 2001,
78(5):379-388.
22. Rutz HP, Herr I: Interference of glucocorticoids with apoptosis
signaling and host-tumor interactions.  Cancer Biol Ther 2004,
3(8):715-718.
23. Zhang C, Mattern J, Haferkamp A, Pfitzenmaier J, Debatin KM,
Hohenfellner M, Rittgen W, Edler L, Groene E, Herr I: Corticoster-
oid-induced chemotherapy resistance in urological cancers.
Cancer Biol Ther 2006, in press:.
24. Zhang C, Kolb A, Gassler N, Wenger T, Herzer K, Debatin KM,
Buechler M, Edler L, Rittgen W, Friess H, Herr I: Dexamethasone
desensitizes hepatocellular and colorectal tumours toward
cytotoxic therapy.  Cancer Letters 2005, in press:.
25. Zhang C, Marme A, Wenger T, Gutwein P, Edler L, Rittgen W, Deba-
tin KM, Altevogt P, Herr I: Glucocorticoid-mediated inhibition
of chemotherapy in ovarian carcinomas.  Int J Oncol 2006,
28(2):551-8.
26. Muenstedt K, Borces D, Bohlmann MK, Zygmunt M, von Georgi R:
Glucocorticoid administration in antiemetic therapy.  Cancer
2004, 101:1696-1702.
Additional File III
DEX induces resistance ex vivo Tumour cells from 20 patients (No. 1-
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(0.1, 1 or 10 µM as indicated) for 24 h. Gemcitabine or cisplatin were 
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Additional File IV
DEX induces resistance ex vivo Tumour cells from 20 patients (No. 1-
20) with pancreatic cancer were freshly isolated and cultivated in a con-
centration of 5 × 105/ml in the absence (white bars) or presence of DEX 
(0.1, 1 or 10 µM as indicated) for 24 h. Gemcitabine or cisplatin were 
added in concentrations indicated while the controls remained untreated 
(CO) or were treated with the solvents alone. 24, 48 and 72 h after add-
ing cytotoxic drugs, viability was measured by the MTT-assay. Eight wells 
per treatment were analyzed and standard deviations are less than 10%.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-6-61-S4.pdf]
Additional File V
DEX induces resistance ex vivo Tumour cells from 20 patients (No. 1-
20) with pancreatic cancer were freshly isolated and cultivated in a con-
centration of 5 × 105/ml in the absence (white bars) or presence of DEX 
(0.1, 1 or 10 µM as indicated) for 24 h. Gemcitabine or cisplatin were 
added in concentrations indicated while the controls remained untreated 
(CO) or were treated with the solvents alone. 24, 48 and 72 h after add-
ing cytotoxic drugs, viability was measured by the MTT-assay. Eight wells 
per treatment were analyzed and standard deviations are less than 10%.
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